StockNews.com assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC – Free Report) in a research report sent to ...

Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC – Get Free Report) have been given a consensus recommendation of “Hold” by the nine analysts that are presently covering the stock, Marketbeat.com ...

Alan H. Bryce, MD, discusses areas of need to help guide treatment decisions in the clinic for prostate cancer management.

Good morning, ladies and gentlemen, and welcome to the LENZ Therapeutics Year End 2024 Financial ... by commercial launch activities in the United States, with products anticipated to be available ...

SILVER SPRING, Md. (AP) — SILVER SPRING, Md. (AP) — United Therapeutics Corp. (UTHR) on Wednesday reported fourth-quarter net income of $301.3 million. The Silver Spring, Maryland-based company said ...

Bayer AG BAYRY recently announced that the FDA had accepted its supplemental new drug application (sNDA) seeking approval for ...

DURHAM, NC, UNITED STATES, March 5, 2025 /EINPresswire.com/ -- Hudson Therapeutics, the U.S. subsidiary of Shaperon, announced today that Shaperon will commence the ...

"We are delighted that CTD402 has received IND clearance from the US FDA for a phase 1b/2 trial with a simplified dose-finding design, accelerating our clinical development timeline in the United ...

BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its GAAP profit of $6.19 per ...